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The adaptor protein paxillin contains five conserved
leucine-rich (LD) motifs that interact with a variety
of focal adhesion proteins, such as a-parvin. Here,
we report the first crystal structure of the C-terminal
calponin homology domain (CHC) ofa-parvin at 1.05 A˚
resolution and show that it is able to bind all the LD
motifs, with some selectivity for LD1, LD2, and LD4.
Cocrystal structures with these LD motifs reveal the
molecular details of their interactions with a common
binding site on a-parvin-CHC, which is located at the
rim of the canonical fold and includes part of the
inter-CH domain linker. Surprisingly, this binding
site can accommodate LD motifs in two antiparallel
orientations. Taken together, these results reveal an
unusual degree of binding degeneracy in the paxil-
lin/a-parvin system that may facilitate the assembly
of dynamic signaling complexes in the cell.
INTRODUCTION
Cell adhesion and migration are coordinated by dynamic mem-
brane-associated protein assemblies called focal adhesions
(FAs). With over 150 components, FAs play a crucial role in trans-
mitting signals bidirectionally across the cell membrane and
provide a physical link between integrin receptors and the actin
cytoskeleton (Zaidel-Bar et al., 2007). The ordered recruitment of
signaling and cytoskeletal proteins to FAs relies on a number of
adaptor proteins, such as paxillin. Paxillin is composed of a
33 kDa N-terminal region and four C-terminal LIM domains. It
is among the most-connected FA proteins and is implicated in
the localization of various proteins during adhesion assembly
(Brown and Turner, 2004). Many of its ligands bind to highly con-
served leucine-rich sequences with the consensus LDXLLXXL
(‘‘LD motifs’’), located in the N-terminal region of paxillin. LD-
binding proteins include the kinases FAK (Turner et al., 1999),
ILK (Nikolopoulos and Turner, 2001), and PAK3 (Hashimoto
et al., 2001), the Arf-GAP PKL (Turner et al., 1999), the antiapop-
totic protein Bcl-2 (Sheibani et al., 2008), the papillomavirus
oncoprotein E6 (Tong et al., 1997), and the cytoskeletal proteins
vinculin (Turner et al., 1999) and a-parvin (Nikolopoulos and
Turner, 2000). While several of these proteins, such as FAK,
PKL, and vinculin, bind LD motifs through parallel a-helical bun-Structure 16, 1521dles (Gao et al., 2004; Hoellerer et al., 2003; Liu et al., 2002;
Scheswohl et al., 2008; Schmalzigaug et al., 2007; Zhang
et al., 2008), others employ topologically distinct modules,
such as the kinase domain of ILK (Tu et al., 2001), the BH4 do-
main of Bcl-2 (Sorenson, 2004), and the calponin homology
(CH) domain of a-parvin (Nikolopoulos and Turner, 2000).
a-parvin (Olski et al., 2001), also known as actopaxin (Nikolo-
poulos and Turner, 2000) or CH-ILKBP (Tu et al., 2001), is part of
the ILK signaling complex (Tu et al., 2001), plays an essential role
in adhesion-dependent PKB/Act activation (Fukuda et al., 2003)
and in the regulation of actin organization (LaLonde et al., 2005)
and Rac activation (LaLonde et al., 2005; Zhang et al., 2004). It
belongs to the highly conserved parvin family that shares a com-
mon architecture composed of a variable N-terminal region
followed by two CH domains (Olski et al., 2001). CH domains
are found in a variety of cytoskeletal and signaling proteins, in-
cluding calponin, spectrin, plectin, fimbrin, and a-actinin, and of-
ten occur in tandem to form actin-binding domains (ABDs). How-
ever, the primary sequences of both CH domains of a-parvin are
highly diverged from the typical type-1 and type-2 CH domains
found in ABDs; they have therefore been classified as type-4
and type-5 CH domains (Gimona et al., 2002). An ability to recog-
nize paxillin LD motifs has only been reported for the type-5
CH domains (Nikolopoulos and Turner, 2000; Yoshimi et al.,
2006).
Here, we elucidate the molecular basis for selective LD recog-
nition by type-5 CH domains. While this manuscript was in prep-
aration, an independent study reported the NMR structure of the
C-terminal CH domain of a-parvin in complex with a 10-residue
peptide derived from the paxillin LD1 motif (Wang et al., 2008).
Our study significantly extends those findings and provides
a comprehensive description of LD recognition by a-parvin,
revealing a surprising degree of promiscuity in LD mediated
interactions.
We present the first high-resolution crystal structure ofa-parvin-
CHC and show that it interacts with all five paxillin LD motifs in so-
lution. Three cocrystal structures of a-parvin-CHC with 20-residue
peptides representing LD1, LD2, and LD4 allow us to characterize
the interaction at atomic resolution and to highlight binding-
induced conformational changes in a-parvin-CHC. This analysis
together with NMR studies of a spin-labeled LD1 peptide supports
the surprising finding that LD motifs can associate with a single
binding site bidirectionally. Using the full-length protein we further
demonstrate that the N-terminal region of a-parvin is not involved
in LD-recognition, providing further validation for our molecular
model of LD recognition by a-parvin-CHC.–1531, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1521
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Paxillin LD Interactions with a-ParvinFigure 1. Structure of a-Parvin-CHC
(A) Schematic of the domain structure of a-parvin according to SMART (Schultz et al., 1998) and the crystallized fragment a-parvin-CHC.
(B) Superposition of the ribbon representations of a-parvin-CHC in blue and the type-1 CH domain of a-actinin 3 (residues 42 to 149 of 1WKU) in red. Canonical
secondary structural elements include helices aA (258–279), aC (294–304), aE (320–336), aF (346–350), and aG (354–368). Features unique to a-parvin, such as
the N-linker helix (249–256) and the C/E-loop containing the 3-residue insertion (313–315), are highlighted.
(C) Sequence alignment of a-parvin-CHC with type-5 CH domains of other members of the parvin family. Secondary structure elements are indicated as above.
Note that aD (310–312) is only found in 1 of 2 molecules in the asymmetric unit.RESULTS
Crystal Structure of the C-Terminal Type-5 CH Domain
of a-Parvin
We initially attempted to solve the crystal structure of full-length
human a-parvin, but no crystals could be obtained. However,
limited proteolysis led to the identification of a stable fragment,
a-parvin-CHC, that readily crystallized. This fragment includes
residues 242–372 and thereby spans the entire C-terminal CH
domain as defined by SMART (Schultz et al., 1998) and a portion
of the inter-CH domain linker (Figure 1A). The crystal structure of
a-parvin-CHC at 1.05 A˚ resolution was determined by molecular
replacement using an ensemble of homologous type-1 CH do-
main structures as search model. Data collection and refinement
statistics are summarized in Table 1. The refined structural
model includes a-parvin residues 246–372 (molecule A) or
247–372 (molecule B) and represents the first high-resolution
crystal structure of a type-5 CH domain (Figure 1B). In spite of
very low levels of sequence conservation (%26% identity) com-
pared to canonical type-1 CH domains (see Figure S1 available
online), a-parvin-CHC exhibits a typical CH domain core com-
posed of four main a-helices (aA, aC, aE, and aG; nomenclature
from Djinovic Carugo et al., 1997), which are connected by loops
and shorter helical elements (aD and aF). Secondary structure
matching (Krissinel and Henrick, 2004) of a-parvin-CHC with its
closest homolog, the type-1 CH domain of a-actinin 3 (PDB:
1WKU), yields an RMSD of 1.19 A˚ in 103 equivalent Ca-positions.
Atypically, however, the N-terminal boundary of a-parvin-CHC is
extended by a short a-helix comprising residues 249 to 256. This
‘‘N-linker helix’’ tightly associates with helices A and G of the
canonical CH domain through electrostatic interactions (of resi-
dues D248, D251, and D255 with K355 and R359 in aG) and
hydrophobic contacts (of residues F250, L253, and F254 with
L354, K355, L358, and R359 of aG and K260 and L261 of aA).
We therefore conclude that the N-linker helix forms an integral1522 Structure 16, 1521–1531, October 8, 2008 ª2008 Elsevier Ltd Apart of the type-5 CH domain of a-parvin, which is in agreement
with its resistance to proteolysis. Another feature peculiar to
this type-5 CH domain is the loop between helices C and E,
which contains a 3 (or 4)-residue insertion (relative to type-1
CH domains) that is conserved throughout the parvin family
(Figures 1C and S1). However, conformational differences in
this region may not be significant, since the C/E-loop structure
varies between a-parvin-CHC molecules both in the same and
different crystal forms and is involved in crystal packing (data
not shown).
Interaction of aParvin-CHC with Paxillin LD Peptides
in Solution
On the basis of primary sequence comparison with other LD-
binding proteins, such as FAK and vinculin, and mutation stud-
ies, the LD-binding site (or ‘‘paxillin binding subdomain’’ [PBS])
of a-parvin was mapped to residues 274–291 (Nikolopoulos
and Turner, 2000) (i.e., the A/C-loop of a-parvin-CHC) (Figure 1B).
However, we previously demonstrated that LD-binding to the
FAT domain of FAK does not reside in a local peptide sequence
such as the PBS (Hoellerer et al., 2003) and thus investigated the
interaction of a-parvin-CHC with LD motifs using solution NMR.
1H-15N HSQC monitored titrations of 15N-enriched a-parvin-CHC
were performed with peptides representing all five paxillin LD
motifs. Each peptide was found to induce resonance-specific
chemical shift perturbations (Figure 2 and data not shown),
indicating an interaction with a-parvin-CHC. Global fitting of the
resulting binding curves shows that the affinities of individual
LD motifs for aparvin-CHC differ substantially (Table 2; Fig-
ure S2) with LD1 being the highest affinity ligand followed
by LD4 and LD2. All three bind with affinities in the micromolar
range, while LD3 and LD5 bind in the millimolar range. The overall
pattern of chemical shift perturbations induced by saturating
concentrations of different LD peptides is very similar (Figure 2),
suggesting that all five LD motifs interact with a-parvin-CHCll rights reserved
Structure
Paxillin LD Interactions with a-ParvinTable 1. Data Collection and Refinement Statistics
Data Collection
Name CHC CHC/LD1 CHC/LD2 CHC/LD4
Space group P21 C2 C2221 C2221
Cell dimensions 44.14, 71.20, 47.15 133.12, 37.50, 70.24 74.01, 94.42, 41.84 75.42, 94.60, 42.17
a,b,c (A˚) 90.0, 99.88, 90.00 90.00, 90.33, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
a,b,g ()
X-ray source ESRF ID14-2 ESRF ID23-1 DLS-I04 ESRF-ID29
Wavelength (A˚) 0.933 0.969 0.968 0.976
Resolution (A˚) 23.741.05
(1.111.05)
28.642.10
(2.212.10)
27.711.80
(1.901.80)
37.722.20
(2.322.20)
I/sI 16.5 (2.4) 16.4 (2.5) 13.2 (3.2) 9.7 (2.2)
Completeness (%) 93.7* (77.7) 98.5 (99.4) 99.6 (100) 99.5 (100)
Rsym (%) 4.0 (46.0) 5.4 (44.9) 7.1 (35.1) 11.9 (63.4)
Redundancy 4.2 (3.5) 2.9 (3.0) 3.4 (3.5) 3.5 (3.6)
Model Refinement
Resolution (A˚) 1.05 2.1 1.8 2.2
Rwork/Rfree (%) 14.3/15.9 21.7/25.5 18.6/22.1 20.5/26.0
No. atoms
Protein(+ peptide) 2777 2765 1373 1333
Ligand/ion 30 92 43 41
Water 279 85 65 39
B-factor average
Protein 11.5 42.2 24.3 30.90
Peptide 44.7 27.7 35.08
RMS deviations
Bond lengths (A˚) 0.014 0.007 0.010 0.008
Bond angles () 1.69 1.13 1.23 1.14
Values in parentheses are for the highest-resolution shell. One crystal was used for each data collection.
* >96% in each shell until 1.3 A˚ resolution.in a similar fashion. Large chemical shift perturbations (dD1H15N)
R 0.2 ppm) map to the N-linker helix, helix A, and helix G,
whereas the central region is less affected.
Crystal Structures of a-Parvin-CHC in Complex
with Paxillin LD Motifs
To elucidate the molecular basis for LD recognition by a-parvin-
CHC, we cocrystallized a-parvin-CHC with peptides representing
the high-affinity ligands LD1, LD2, and LD4. The corresponding
Table 2. Dissociation Constants for the Interaction of a-Parvin
with Paxillin LD Motifs
Protein Peptide KD (mM) Method
a-parvin-CHC LD1 96 ± 2 NMR
a-parvin-CHC LD2 204 ± 3 NMR
a-parvin-CHC LD3 2300 ± 100 NMR
a-parvin-CHC LD4 140 ± 30 NMR
a-parvin-CHC LD5 mM range
a NMR
a-parvin-CHC LD1 120 ± 20 Fluorescence anisotropy
full-length a-parvin LD1 130 ± 22 Fluorescence anisotropy
a No accurate KD-value could be obtained for LD5 due to its low affinity for
aparvin-CHC.Structure 16, 1521structures at 2.1 A˚, 1.8 A˚, and 2.2 A˚ resolution, respectively,
were solved by molecular replacement with the a-parvin-CHC
apo structure (Table 1). In all three cases, continuous positive
difference density was identified into which the peptide ligands
could be placed unambiguously (Figure S3). The refined struc-
tures include residues 247–372 of a-parvin and paxillin residues
1–14, 141–155, and 262–274 for LD1, LD2, and LD4, respectively
(Figures 3A and 4). The remaining C-terminal residues of the LD
peptides appear disordered, presumably because they do not
form contacts with a-parvin-CHC (Figure 3B). All three LD motifs
bind to the same binding site on a-parvin-CHC formed by the
N-linker helix, the N-terminal part of helix A and the C-terminal
part of helix G, which is consistent with our results from chemical
shift mapping (Figure 2). We thus conclude that the PBS region
previously identified on a-parvin is not directly involved in the in-
teraction with LD peptides.
Surprisingly, however, the orientation of LD1 is reversed com-
pared to LD2 and LD4 in the corresponding crystal structures. To
confirm this striking result, we built models corresponding to
both possible orientations for each LD-peptide complex and
subjected them to simulated annealing refinement using PHENIX
(Afonine et al., 2007). Inspection of the resulting difference maps
unambiguously confirmed that LD1 is oppositely aligned to LD2
and LD4. From this point forward, the orientation of LD1 in the–1531, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1523
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Paxillin LD Interactions with a-Parvincrystalline state will be denoted as ‘‘forward,’’ and the orientation
of LD2/LD4 will be denoted as ‘‘backward.’’
The observation of bidirectionality in this system was unex-
pected, since all three LD motifs form amphipathic a-helices
when bound and thus do not possess C2-rotational symmetry.
Despite their antiparallel orientations, however, the binding
modes of different LD peptides are very similar (Figure 3A, Fig-
ure S4). As the result of a slight rotation around the helical axis
of the bound peptides, the character and position of side chains
facing a-parvin-CHC is largely preserved, the same hydrophobic
pockets are occupied, and a similar amount of surface area
(500 A˚2) becomes buried. We adopt a nomenclature in which
the first conserved leucine residue of an LD motif is labeled
position 0. The side chains of their conserved leucine residues
in position 0, +3, +4, and +7 (Figure 3B) interact with a hydropho-
bic patch on the surface of the CHC domain formed by residues
from the N-linker helix (A249, F250, L253, A257), helix A (V263,
V264, and L268) and helix G (Y362 and F365) (Figure 3A). In
addition, two positively charged residues (K260 and R369) of
a-parvin-CHC are in close proximity to negatively charged resi-
dues of the bound LD peptides. Note that these electrostatic
contacts involve the conserved aspartate D+1 of the LD consen-
sus in the case of LD2 and LD4, whereas D+6 and E+8 are
utilized in LD1. Because of the reverse binding orientation D+1
of LD1 faces away from the binding site and toward R247 and
H256 in a symmetry-related copy of a-parvin-CHC. On the basis
of the probability of the solvation free energy gain upon contact
formation (Krissinel and Henrick, 2004), the latter interface is
probably an artifact of crystal packing.
Consistent with their similar binding modes (Figure S4), all
three LD peptides, irrespective of directionality, impose similar
conformational changes in the N-terminal region of a-parvin-
CHC, whereas the protein core remains virtually unperturbed
(Figure 4). In particular, residues 248 to 264, which experience
conformational change upon complex formation, are similar in
Figure 2. NMR Titrations of a-Parvin-CHC with Paxillin LD Peptides
Weighted combined chemical shift perturbations extrapolated to saturating
ligand concentrations along the sequence of a-parvin-CHC. Grey patches
denote unassigned residues or residues broadened due to intermediate
exchange (residues 253 and 268). Note that the overall higher amplitudes for
LD4 might be due to the relatively high error in the extrapolation to full satura-
tion. LD5 was excluded from this plot, since full saturation could not be
achieved.1524 Structure 16, 1521–1531, October 8, 2008 ª2008 Elsevier Ltdall LD complexes with RMSD-values of 0.28 A˚ (LD1 versus
LD2), 0.23 A˚ (LD1 versus LD4), and 0.15 A˚ (LD2 versus LD4)
in 16 equivalent Capositions. Compared with a-parvin-CHC
apo, the angle between the N-linker helix and helix A widens
by 15 and the N-linker helix rotates slightly. Residues 258–
260 of helix A, which are a-helical in the unbound conformation,
adopt a 310-helix in the complexes. The short loop surrounding
P258 between the N-linker helix and helix A reorganizes to
accompany this conformational change, as has been seen for
proline-containing hinge-regions that delimit conformational
changes in other proteins (Figure 4).
Directionality of LD1 Binding to aParvin-CHC
in Solution
We next asked the question whether the direction of LD-binding
to a single site on a-parvin-CHC is a function of the primary
sequence of the ligand. A sequence alignment shows that the
LD1 motif has noticeable pseudo-palindromic features with re-
spect to those residues critical for the interaction with aparvin
(Figure 3B), raising the possibility that it might be able to associ-
ate with a-parvin-CHC bidirectionally. To test this hypothesis and
to explore the role of electrostatic interactions, LD1 peptide var-
iants were synthesized in which residues D+1 and D+6, which
are predicted to form orientation-specific electrostatic contacts,
were substituted by alanine either individually or in combination
(D+1A, D+6A or D+1A/D+6A). As measured by NMR, none of
these substitutions substantially altered the binding affinity for
a-parvin-CHC, indicating that the predicted electrostatic con-
tacts are energetically neutral under the assay conditions
(50 mM sodium phosphate and 100 mM NaCl [pH 6.9]) used.
Therefore, analysis of LD1 peptide variants did not define the
binding mode of LD1 in solution. Likewise, comparison of the
chemical shift perturbations imposed by oppositely aligned pep-
tides on backbone amide resonances of a-parvin-CHC (Figure 2)
is inconclusive. We note that the peptide side-chains contacting
the LD-binding site of a-parvin-CHC are similar in either orienta-
tion (Figure S4), as is the conformational rearrangement induced
by peptide binding, so that the perturbation patterns of either
unidirectional binding mode (or a bidirectional mixture) may be
indistinguishable.
The binding orientation of LD1 in solution was therefore studied
by paramagnetic relaxation enhancement (PRE) measurements
using an N-terminally PROXYL-labeled peptide derivative. Spin
labels increase nuclear relaxation rates and consequently lead
to a loss of resonance intensity in a distance dependent manner
(usually within a radius of about 20 A˚). Consequently, the addition
of PROXYL-labeled LD1 to 15N-enriched a-parvin-CHC was
expected to result in distinct PRE effects depending on binding
orientation. The KD-values of PROXYL-labeled and underivatized
LD1 peptide for a-parvin-CHC were found to be the same (data
not shown), suggesting that the spin-label does not significantly
perturb the interaction.
On the basis of the cocrystal structures of a-parvin-CHC with
LD1 and LD4, we calculated theoretical PRE values for all protein
NH resonances corresponding to either forward or backward
binding modes, respectively. Interestingly, the experimentally
derived PRE data resemble a mixture of the two simulated
PRE profiles (Figure S5A). This phenomenon is also illustrated
in Figure 5, using two diagnostic NMR signals as examples:All rights reserved
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Paxillin LD Interactions with a-ParvinFigure 3. Cocrystal Structures of a-Parvin-CHC with Paxillin LD1, LD2, and LD4
(A) Detail of the a-parvin-CHC complexes with LD1 (top), LD2 (middle), and LD4 (bottom). The left panel shows electrostatic surface renditions of a-parvin-CHC
with the bound LD peptides represented by a combination of ribbon, ball-and-stick (side-chains), and cylinder (main chain) modes to indicate directionality. The
right panel shows ribbon representations of a-parvin-CHC (gold) and LD peptides including those side-chains within a contact radius of 4 A˚ as ball-and-stick
models.
(B) Sequence alignment of LD peptides. Those residues ordered in the crystals are underlined; acidic residues are colored red, and basic ones are blue. Residues
in contact with the protein within a radius of 4 A˚ are boxed. The pseudo-palindromic axis of LD1 is shown as a dashed line.the resonance originating from residue 257 is predicted to expe-
rience strong PRE in the forward mode (calculated distance from
spin-label 10.7 A˚) but should only be weakly affected in the back-
ward mode (calculated distance 20.2 A˚). The opposite behavior
should apply to the resonance assigned to residue 370 (calcu-Structure 16, 1521lated distances of 23.3 A˚ in forward versus 14.1 A˚ in backward
mode). However, our experimental data show that both reso-
nances undergo significant broadening, suggesting that a simple
unidirectional model may be insufficient to describe LD1 binding
in solution. To quantify this observation, we calculated the linear–1531, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1525
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Paxillin LD Interactions with a-Parvincorrelation coefficients, R, between the experimental and the
simulated PRE data for various ratios of forward-to-backward
binding in a bidirectional mixture (Figure S5B). The resulting
curve is bell shaped, indicating that the experimental data are
more consistent with a bidirectional than a unidirectional binding
model. The best correlation, with a value of 0.8, is generated by
a model corresponding to a forward-to-backward ratio of
75%/25%. Although the improvement on R upon consider-
Figure 4. Cocrystal Structure of a-Parvin-CHC with Paxillin LD1
Superposition of the ribbon representations of a-parvin-CHC in blue and its
complex with the LD1 peptide in gold and green, respectively. Secondary
structural elements are indicated.ation of a bidirectional model is small, F-test analysis between
the unidirectional forward and this optimal bidirectional model
shows that the improvement in the later is statistically significant
(p < 0.001), and argues for the presence of both binding orienta-
tions in solution. The observation that no model returns an R value
of 1.0 may reflect both the neglect of peptide flexibility in the PRE
simulation, in particular the dynamic process of LD1 helix forma-
tion ona-parvin-CHC, and/or nonspecific effects of the spin label.
In conclusion, our analysis provides support for the hypothesis
that both antiparallel binding modes are accessible to the LD1
peptide in solution.
Comparison of LD1 Binding to a-Parvin-CHC
and Full-Length a-Parvin
To establish whether the N-terminal region of aparvin, which is
excluded from our structural analysis, contributes to LD recogni-
tion, we compared binding of a fluorophore-labeled LD1 peptide
to either a-parvin-CHC or full-length a-parvin by fluorescence
anisotropy. Both binding curves could be fitted by a single
site model, suggesting that a-parvin contains only one LD-bind-
ing site located within the CHC fragment (Figure S6). The resulting
KD-value for a-parvin-CHC is similar to the corresponding
value obtained by NMR, supporting the validity of our results (Ta-
ble 2). Importantly, the KD-values fora-parvin-CHC and full-length
a-parvin are the same within error (Table 2), suggesting that the
N-terminal region of a-parvin (residues 1–242) makes little net
contribution to LD binding. We thus conclude that the crystal
structures of the a-parvin-CHC/LD complexes along with the
solution NMR studies presented here provide a relevant descrip-
tion of LD recognition by a-parvin.
DISCUSSION
We have applied a combination of high-resolution X-ray crystal-
lography and solution techniques to characterize the recognition
of paxillin LD motifs by a-parvin. Our results demonstrate that
full-length a-parvin contains a single LD binding site, formed
by the N-linker helix, helix A, and helix G of the C-terminalFigure 5. PRE Experiment with Spin-Labeled LD1
(A) Details of the 1H-15N HSQC spectra of 230 mM 15N-enriched a-parvin-CHC and 250 mM PROXYL-labeled LD1 peptide in the absence (left) and presence (right)
of 5 mM ascorbate. The latter serves to reduce the spin label, thereby eliminating PRE effects. The binding orientation of LD1 seen in the crystal structure is
denoted ‘‘forward.’’
(B) Ribbon representation of a-parvin-CHC in gold and LD1 in green. The position of a-parvin residues 257 and 370 are highlighted in blue and red, respectively.
1526 Structure 16, 1521–1531, October 8, 2008 ª2008 Elsevier Ltd All rights reserved
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Paxillin LD Interactions with a-Parvintype-5 CH domain. This binding site is consistent with the one
described in a recent solution NMR structure of a-parvin-CHC
in complex with an LD1 peptide (Wang et al., 2008). Using NMR
titrations, we have shown that this binding site interacts with all
five paxillin LD motifs, exhibiting a preference for LD1, LD2, and
LD4 over the less conserved LD3 and LD5. This could be due to
differences in specific contacts and/or helical propensity of the
latter two LD motifs. In contrast, previous data based on less-
sensitive pull-down experiments suggested thata-parvin binding
is limited to LD1 and LD4 (Nikolopoulos and Turner, 2000). In our
studies, LD1 binds to a-parvin-CHC most tightly and consistently
yields a KD-value of 100 mM independent of the experimental
method employed. The significantly lower value of 1.2 mM re-
cently measured (Wang et al., 2008) might be due to the restricted
length of the peptide (10 versus 20 residues) used in their study.
The relatively low degree of selectivity for individual LD motifs
seen for a-parvin-CHC is reminiscent of the low selectivity re-
ported for other LD-binding proteins. The FAT domain of FAK
contains two independent LD binding sites, which bind equally
well to LD2 and LD4 in vitro (Hoellerer et al., 2003; Gao et al.,
2004), but it also interacts to some degree with the other LD motifs
(M.K.H., unpublished results). Recent NMR studies (Zhang et al.,
2008) have also demonstrated that the single LD binding site of
PKL/GIT1 binds to both LD4 (Turner et al., 1999) and LD2. Taken
together, these observations suggest that paxillin LD motifs are
promiscuous protein interaction modules. This degeneracy can
be explained by the high similarity of those residues of individual
LD motifs that form the interacting surface of the amphipathic
helix (Figures 3 and S4). A higher degree of specificity may be
achieved in the context of full-length paxillin and/or through the
interplay of several LD binding partners in vivo.
On the basis of our results for a-parvin, we can make two gen-
eral predictions with respect to LD recognition by CH domains:
First, as noted previously (Wang et al., 2008), we propose that
the presence of an N-linker helix is a prerequisite for the interac-
tion with LD motifs. In agreement with this hypothesis, it has
been reported that a-actinin, whose canonical CH domains
lack this structural element, does not interact with paxillin (Niko-
lopoulos and Turner, 2000). Since the C-terminal region, includ-
ing the N-linker helix, is highly conserved throughout the parvin
family, we speculate that all parvin paralogs may be able to
bind LD motifs. Interestingly, g-parvin was shown to associate
with paxillin in vivo (Yoshimi et al., 2006). Available experiments
with b-parvin, however, have proved negative to date (Yamaji
et al., 2004), although this protein is more similar in sequence
to a-parvin than is g-parvin (Figure 1C). Second, on the basis
of the analysis of differential binding of a-parvin-CHC to individ-
ual paxillin-derived LD motifs, we can predict which LD motifs in
the paxillin paralogs Hic-5 and leupaxin are likely to be ligands
for a-parvin. The sequence alignment in Figure 6 demonstrates
that only LD1 is sufficiently conserved in the case of leupaxin,
whereas Hic-5 contains three potential a-parvin-binding LD
motifs, a hypothesis borne out by experiment (Nikolopoulos
and Turner, 2000). Although no interaction of leupaxin with
a-parvin has yet been reported, we propose that it will interact
with a-parvin via its LD1 motif. Members of the paxillin and parvin
families are differentially expressed in human tissues (http://
www.hprd.org), and it is possible that they may form tissue-
specific complexes.Structure 16, 152The structure of a-parvin-CHC is topologically distinct from
other LD-binding domains, such as the FAT domain of FAK; it as-
sociates with a single LD motif across three oblique helices,
whereas FAT accommodates two LD motifs in parallel fashion
on opposite sites of its 4-helical bundle (Hoellerer et al., 2003).
This suggests that recognition of paxillin LD motifs does not de-
pend on a conserved fold. However, the surface properties of the
LD binding sites of a-parvin and FAT are similar, consisting of
a hydrophobic patch flanked basic residues. In both cases, LD
motifs adopt an a-helical conformation when bound, which al-
lows the conserved leucine residues on one face of the helix to
interact with the hydrophobic binding site. Notably, the role of
electrostatic contacts in LD recognition might differ between
the two proteins: while substitutions of the conserved aspartates
(D+1) of LD2 and LD4 to alanine were found to abolish the inter-
action of N-terminal paxillin fragments with FAT (Brown et al.,
1996; Scheswohl et al., 2008; Thomas et al., 1999), our study
and others (Wang et al., 2008) show that the equivalent substitu-
tions in the isolated LD1 peptides do not significantly perturb
a-parvin-CHC binding in vitro.
Our crystallographic studies reveal that the LD-binding site on
a-parvin-CHC can accommodate different paxillin LD motifs in
either of two antiparallel orientations. Bidirectional protein-ligand
interactions are widespread among PPII (poly-proline type-2)
helical ligands, as this conformation has a pseudo C2-rotational
symmetry perpendicular to its long axis (Ball et al., 2005). In con-
trast, bidirectional recognition of a-helices is relatively rare, since
these ligands do not generally demonstrate C2-rotational sym-
metry. To our knowledge, this phenomenon has only been
reported for the following: the recruitment of the histone deacte-
lylase-associated Sin3 corepressor by the HBP1 and Mad1
repressors, respectively (Brubaker et al., 2000; Spronk et al.,
2000; Swanson et al., 2004), the association of FAT with paxillin
LD motifs and the endocytosis motif of CD4 (Garron et al., 2008),
Figure 6. Conservation of a-Parvin Contacting Residues in LD
Motifs of Paxillin Paralogs
Sequence alignment of LD motifs in human paxillin (PAXN), hic-5 (HIC5),
and leupaxin (LPXN). Paxillin residues ordered in the crystal structures of the
a-parvin-CHC/LD complexes are underlined and those forming contacts with
a-parvin-CHC within a radius of 4 A˚ are boxed.1–1531, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1527
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PKA (Gold et al., 2006). In the system studied here, bidirection-
ality is related to the pseudo-palindromic character of the LD
consensus and the resulting resemblance of the interfaces
formed by oppositely aligned LD motifs with a-parvin-CHC.
Our global analysis of the PRE effects of spin-labeled LD1
(paxillin residues 1–20) on a-parvin-CHC resonances indicates
that forward and backward binding modes may be simulta-
neously accessible to the same peptide in solution, implying sim-
ilar binding energies for the two modes; the 3:1 apparent ratio
observed for LD1 at room temperature corresponds to a differ-
ence in binding energy of just 2.7 kJ mol1. Small changes in
a variety of factors, such as experimental conditions or the length
of the paxillin fragment studied, might influence the observed
binding orientation in NMR, where a mean is detected. This could
explain a similar PRE experiment performed with a shorter LD1
variant (residues 3–13), which was interpreted as unidirectional
forward-type binding and used to restrain the solution structure
of the LD1/a-parvin-CHC complex (Wang et al., 2008).
Although our PRE experiments suggest bidirectional binding
in solution, the refinement of different models against our X-ray
data strongly indicate a predominance of the forward binding
mode in the a-parvin-CHC/LD1 crystal. At the same time, the
TLS-corrected individual isotropic temperature factors of the
LD-peptides are not atypical of those expected for weakly bound
ligands (data not shown): deviation from such behavior would be
expected if the crystal contained significant static disorder in
peptide binding. Taken together, these observations suggest
that a unidirectional complex is purified to homogeneity by the
process of crystallization. In both the forward and backward
binding mode, LD peptides make a small number of crystal con-
tacts. The capacity of such relatively weak crystal-packing
forces to bring about homogenization of orientation is consistent
with our finding that the two different orientations are approxi-
mately isoenergetic in solution.
Although aparvin has been shown to bind to F-actin with an
affinity comparable to other CH domain-containing actin-binding
proteins (Nikolopoulos and Turner, 2000; Olski et al., 2001), the
canonical model of actin recognition may not apply to this pro-
tein. Usually CH domains bind F-actin through a tandem array
of an N-terminal type-1 CH domain containing two actin-binding
sites (ABS1 and ABS2) and a C-terminal type-2 CH domain con-
tributing a third actin-binding site (ABS3) (Gimona et al., 2002).
However, both CH domains of a-parvin are atypical and more
similar in sequence to type-1 than type-2 CH domains. Despite
some sequence conservation in the regions homologous to
ABS1 and ABS2, many of the critical residues, which are highly
conserved across type-1 CH domains of actin-binding proteins,
are absent in a-parvin-CHC (Figure S1). Interestingly, the crystal
structure of aparvin-CHC presented here shows that part of the
putative ABS2 region is obstructed by the N-linker helix. We have
also shown that helices A and G, which contain the putative
ABSs, are involved in the binding of paxillin LD motifs, which
could render the interaction of aparvin with paxillin and F-actin
mutually exclusive.
We have shown that LD binding imposes conformational
changes in the most N-terminal region of the a-parvin-CHC do-
main. If these effects are propagated to the N-terminal regions
of a-parvin, they might affect the conformation of the inter do-1528 Structure 16, 1521–1531, October 8, 2008 ª2008 Elsevier Ltdmain linker and/or potential interactions between the two CH
domains. CH domains in intact ABDs often interact across a size-
able interface, which can modulate their ability to interact with
F-actin (Gimona et al., 2002). It remains to be established
whether such intramolecular interactions occur to regulate
the association of a-parvin with F-actin and other binding part-
ners, such as paxillin, TESK1 (LaLonde et al., 2005), and ILK
(Tu et al., 2001).
Several ABD containing proteins are capable of forming
dimers, thereby cross-linking actin filaments (Gimona et al.,
2002). On the basis of gel filtration experiments with the N-termi-
nal CH domain of a-parvin, Wang et al. (2008) speculate that
a-parvin might also dimerize. However, the full-length protein
is predominantly monomeric under the conditions used in our
experiments (data not shown).
Taken together, we have presented a comprehensive struc-
tural characterization of the interaction between paxillin LD
motifs and a-parvin, which has revealed a surprising degree of
promiscuity, both in terms of LD motif selectivity and binding
directionality. Although it is unclear how these features are
exploited and dynamically regulated in vivo, we speculate that
they may have a role in the context of paxillin-mediated supra-
molecular assemblies. The existence of multiple a-parvin-bind-
ing LD motifs in paxillin has at least two potential advantages.
Engagement of one motif will increase the effective local concen-
tration of others and render weak interactions functional, even in
the presence of stronger LD-binding partners, such as FAK. Two
possible binding orientations will also enhance effective associ-
ation rates in a diffusion-controlled reaction by increasing
the number of productive encounters. Such features may allow
the assembly of various constitutionally and conformationally
distinct protein complexes with specific signaling properties.
EXPERIMENTAL PROCEDURES
Proteins
Full-length human a-parvin (1–372) and a-parvin-CHC (242–372) were subcl-
oned from I.M.A.G.E. Consortium cDNA clone no. 4065758 into the expression
vector pGEX-6P1 (GE Healthcare) via EcoRI/EcoRI and BamHI/EcoRI restric-
tion sites, respectively. The boundaries of a-parvin-CHC were determined by
limited proteolysis: 160 mg a-parvin (residues 223–372) were incubated with
0.1 mg subtilisin A (Sigma) at 25C for 1 hr; the reaction was stopped by adding
protease inhibitor cocktail (Roche), and samples were subjected to N-terminal
sequencing and ESI-MS.
Full-length a-parvin and a-parvin-CHC were expressed as GST-fusions in
Escherichia coli BL21 at 20C overnight in LB medium. Uniform isotopic en-
richment was achieved by using 15N-enriched ammonium sulfate (Spectra
Stable Isotopes), and unenriched or 13C-enriched glucose (Spectra Stable Iso-
topes). a-parvin-CHC was purified as follows: cleared cell lysate (in 75 mM Tris
[pH 8.0], 200 mM NaCl, 5 mM b-mercaptoethanol, 0.4% Triton X-100, 2 mM
EDTA, 5 mM benzamidine, and protease inhibitor cocktail [Roche]) was
applied to glutathione sepharose 4B (GE Healthcare) in binding buffer
(20 mM Tris [pH 8.0], 150 mM NaCl, and 2 mM DTT) washed with 20 mM
Tris (pH 8.0), 1 M NaCl, 2 mM DTT, 2 mM EDTA, and 5 mM benzamidine,
and was eluted with 50 mM glutathione in binding buffer (pH 8.0). After cleav-
age with recombinant human rhinovirus 3C-protease, the sample was
subjected to size exclusion chromatography (Superdex 75, GE Healthcare)
in 25 mM Tris (pH 8.0), 150 mM NaCl, 2 mM DTT, and 2 mM EDTA.
To purify full-length a-parvin, cleared cell lysate in 200 mM potassium phos-
phate (pH 8.0), 10 mM NaCl, 5 mM b-mercaptoethanol, 0.4% Triton X-100,
5 mM benzamidine, 2 mM EDTA, and protease inhibitor cocktail (Roche)
was applied to glutathione sepharose 4B (GE Healthcare), washed with
200 mM potassium phosphate, 10 mM NaCl, and 4 mM DTT, and aparvinAll rights reserved
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4C over night. After elution with 200 mM potassium phosphate, 10 mM NaCl,
4 mM DTT, and 2.5% glycerol, the protein was dialyzed into 25 mM potassium
phosphate (pH 8.0), 1.5 mM NaCl, 2 mM DTT, and 2.5% (v/v) glycerol for
subsequent anion exchange chromatography (MonoQ, GE Healthcare) and
gradient elution with 250 mM potassium phosphate (pH 8.0), 15 mM NaCl,
250 mM KCl, 2 mM DTT, and 2.5% glycerol.
Peptides
All synthetic peptides were purchased from Severn Biotech (Kidderminster,
UK) at >95% purity. Concentrations were determined by quantitative amino
acid analysis (Alta Bioscience, Birmingham, UK). Peptides representing
human paxillin motifs included LD1 (residues 1–20: MDDLDALLADLESTT
SHISK), LD2 (141–160: NLSELDRLLLELNAVQHNPP), LD3 (213–232: VRPS
VESLLDELESSVPSPV), LD4 (262–281: ATRELDELMASLSDFKFMAQ) and
LD5 (296–315: PGSQLDSMLGSLQSDLNKLG). To generate spin-labeled LD1
an N-terminally blocked LD1 peptide in which the N-terminal methionine resi-
due was replaced by cysteine was incubated with a 10-fold molar excess of
3-maleimido-PROXYL (Sigma-Aldrich) at 4C overnight. After purification by
HPLC (Jupiter C18, Phenomonex), quantitative labeling was confirmed by
mass spectrometry. For fluorescence anisotropy studies, LD1 with 5-carboxy-
fluorescein (5-FAM) attached to the 3-amino group of the C-terminal lysine was
used.
Crystallization and Data Collection
a-parvin-CHC was crystallized using sitting drop vapor diffusion by mixing 1 ml
of protein (7 mg/ml in 25 mM Tris (pH 8.0), 150 mM NaCl, 2 mM DTT, and 2 mM
EDTA) with 1 ml of reservoir solution (12% [w/v] PEG 8000, 35% [v/v] MPD, and
0.1 M HEPES [pH 7.5]) at 4C. The large prism-shaped crystals were flash
frozen in mother liquor.
Plate-like a-parvin-CHC/LD1 cocrystals were obtained from 8 mg/ml protein
in the presence of a 2-fold molar excess of LD1 peptide in 2 ml sitting drops
containing buffer 28 (20% [w/v] PEG 10000 and 0.1 M HEPES [pH 7.5]) of
Structure Screen 2 (Molecular Dimensions) at 13C and were flash-frozen in
mother liquor including 35% (v/v) glycerol.
Rod-shaped a-parvin-CHC/LD2 cocrystals were grown from 9 mg/ml pro-
tein in the presence of a 2-fold molar excess of LD2 peptide in sitting drops
containing 40% (w/v) PEG 200 and 0.1 M citrate (pH 4.5) at 13C and were
flash-frozen in mother liquor. Rod-shaped a-parvin-CHC/LD4 cocrystals
were grown under similar conditions (40% [w/v] PEG 300 and 0.1 M citrate
[pH 5.2]).
All data were processed using the CCP4 program suite (Collaborative Com-
putational Project, Number 4, 1994).
Structure Calculation and Refinement
The structure of unliganded a-parvin-CHC was solved by molecular replace-
ment with an ensemble of homologous structures (20%–25% sequence iden-
tity) including the CH1 domains of a-actinin1 (residues 30–135 of chain A of
2EYI), a-actinin3 (residues 42–149 of chain B of 1WKU, residues 42–149 of
chain A of 1TJT) and plectin (residues 59–172 of chain A of 1MB8) using the
program PHASER (McCoy, 2007). Manual model building was performed
with COOT (Emsley and Cowtan, 2004), and refinement was performed with
REFMAC5 (Murshudov et al., 1997); occupancies of alternate conformers
were refined with PHENIX (Afonine et al., 2007).
Structures of a-parvin-CHC/LD complexes were solved by molecular re-
placement with the a-parvin-CHC apo structure using PHASER (McCoy,
2007), and refined with REFMAC5, allowing one TLS group per polypeptide
chain. In all models, >98% of the residues lie in the favored Ramachandran re-
gions and none in the disallowed regions.
NMR
Data were recorded on home-built or Bruker spectrometers with 11.7, 14.1,
17.6, and 22.3 T field strengths and processed with NMRPipe (Delaglio
et al., 1995). Backbone chemical shift assignments were obtained using
standard triple resonance experiments. Peptide titration experiments were
performed by mixing two stock solutions (in 50 mM sodium phosphate,
100 mM NaCl, 2 mM DTT, 5% D2O, and 30 mM DSS [pH 6.9]) containing
235 mM 15N-enriched a-parvin-CHC and either no or a maximum concentrationStructure 16, 1521of LD peptide at the required protein/ligand ratios (Figure S2). Phase-sensitive
gradient-enhanced 1H-15N HSQC spectra (Kay et al., 1992) were recorded at
25C. To compare chemical shift perturbations a weighted combined chemical
shift difference Dd(1H15N) was calculated according to
Ddð1H15NÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
dð1HÞsatdð1HÞ0
2
+ 0:04  Ddð15NÞsatdð1HÞ02
q
:
Binding curves for individual resonances were fitted globally to a single-site
model given by
Ddð1H15NÞ=Ddð1H15NÞsat


½Ptot+ ½Ltot+KD

±
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½Ptot+ ½Ltot+KDÞ24½Ptot½Ltot
q
2½Ptot ;
where [Ptot] and [Ltot] denote the concentrations of a-parvin-CHC and LD
peptides, respectively. None of the individual isotherms (with Dd(1H15N)sat >
0.2 ppm) showed significant deviations from this model (Figure S2).
For PRE measurements, 1H-15N HSQC experiments were recorded on
230 mM 15N-enriched a-parvin-CHC in the presence of 250 mM PROXYL-
labeled LD1 peptide in 50 mM sodium phosphate and 100 mM NaCl
(pH 6.9) in the absence and presence of 5 mM ascorbate at 25C. The intensity
ratios I/I0 (where I and I0 denote peak heights in the absence and presence of
ascorbate, respectively) were determined. For the simulation of PRE effects in
both unidirectional binding modes, the crystal structures of a-parvin-CHC
bound to LD1 and LD4 were protonated with the program PDB 2PQR (Dolinsky
et al., 2004). Equivalent peptide residues corresponding to M-3 in LD1 and T-3
in LD4 of the structural models were replaced by cysteine residues and
the distances of their Sg-atoms to individual backbone amide protons of
a-parvin-CHC were determined. The procedure was repeated for 4 different
cysteine rotamers and the distance data were averaged. The resulting values
were used as approximation of the distances, r, of the unpaired electron of the
PROXYL moiety to the backbone amide protons and to derive residue-specific
PRE-values, I/I0, according to (Jain et al., 2001; Johnson et al., 1999) (for
details, see Figure S5).
Fluorescence Anisotropy
Titrations were performed by mixing two stock solutions containing 50 nM
5-FAM-labeled LD1 peptide and either no or 300 mM protein in 100 mM potas-
sium phosphate and 2 mM DTT (pH 8.0). Measurements on a SpectraMax M5
Microplate Reader (Molecular Devices) at 25C with excitation and emission
wavelengths of 485 and 538 nm, respectively, were repeated four times, and
data were fitted globally to a single-site model (see above).
ACCESSION CODES
Atomic coordinates and structure factors have been deposited in the Protein
Data Bank with accession codes 2VZC, 2VZD, 2VZG, and 2VZI for a-parvin-
CHC, CHC/LD1, CHC/LD2, and CHC/LD4, respectively. a-parvin-CHC back-
bone resonance assignments have been deposited in the BioMagResBank
under accession number 15899.
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